5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Recruiting · NCT06630260 · Registry updated 2026-01-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-01-21 | NCT06630260 |
7 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cambridge University Hospitals | Cambridge | United Kingdom | 4 |
| The Royal Marsden Hospital - Drug Development Unit | Sutton | United Kingdom | 2 |
| The Royal Marsden Hospital - Neuro-Oncology Unit | Sutton | United Kingdom | 1 |